Is Prolia Approved for Men?
Yes, Prolia (denosumab) is FDA-approved for men with osteoporosis at high risk for fracture. It's indicated to increase bone mass in men receiving androgen deprivation therapy for nonmetastatic prostate cancer, and for treatment of glucocorticoid-induced osteoporosis in men at high risk for fracture.[1]
How Does Prolia Work in Men?
Prolia is a monoclonal antibody that inhibits RANKL, reducing osteoclast activity and bone breakdown. In men, clinical trials showed it increased bone mineral density by 5-8% at the lumbar spine after three years, compared to placebo, with similar fracture risk reduction as in women.[1][2]
Who Typically Gets Prescribed Prolia for Men?
Men over 70 with osteoporosis, those on long-term hormone therapy for prostate cancer, or men using steroids like prednisone. It's not first-line for all men—doctors often start with bisphosphonates like alendronate unless those fail or aren't tolerated.[2]
What Are Common Side Effects in Men?
Back pain, muscle pain, high cholesterol, and bladder infections occur in about 5-10% of patients. Serious risks include osteonecrosis of the jaw (rare, ~0.04%) and atypical femur fractures. Hypocalcemia is more common in men with low vitamin D, so monitoring is key.[1][3]
How Does Prolia Compare to Other Osteoporosis Drugs for Men?
| Drug | Approval for Men | Dosing | Key Difference |
|------|-------------------|--------|---------------|
| Prolia | Yes (high-risk osteoporosis, prostate cancer therapy) | SubQ every 6 months | Targets RANKL; no oral option |
| Fosamax (alendronate) | Yes | Oral weekly | Bisphosphonate; cheaper generic |
| Forteo (teriparatide) | Yes | Daily subQ injection | Anabolic; builds new bone |
| Tymlos (abaloparatide) | Yes (limited data) | Daily subQ | Similar to Forteo; shorter use |
Prolia suits men needing potent, infrequent dosing but requires dental checks before starting.[2]
When Does Prolia's Patent Expire?
Prolia's main composition patent (US 7,364,736) expires in 2025, with pediatric exclusivity to February 2026. Multiple patents extend protection to 2030 for specific formulations and methods. Biosimilars like Sandoz's Jubbonti launched in the US in March 2024 under patent settlement.4
[1]: FDA Label for Prolia (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125320s215lbl.pdf)
[2]: American College of Physicians Guidelines on Osteoporosis in Men (https://www.acponline.org/clinical-information/guidelines)
[3]: NIH Osteoporosis Overview (https://www.niams.nih.gov/health-topics/osteoporosis)